# DSMM XVII (NCT03948035)

> Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03948035
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Wuerzburg University Hospital
- Conditions: Newly Diagnosed Multiple Myeloma
- Interventions: Elotuzumab; Carfilzomib; Lenalidomide; Dexamethasone; autologous stem cell transplant
- Enrollment: 576
- Primary outcome: Induction phase
- Primary outcome: Maintenance phase

## Indexed commentary on DSMM XVII so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dsmm-xvii-nct03948035